Aging Frailty


4 clinical trials enrolling >100 patients indicate that MSCs have a positive impact on biological processes connected to aging and demonstrate their safety

Key Insights

Improved physical performance: physical performance improved after allogeneic MSC infusions, measured for instance by the 6-minute walk test. Female sexual quality is also reported to be improved by MSC infusions.

Improved inflammatory bio-markers: the inflammatory levels in the body decreased after allogenic MSC infusions, for instance the serum TNF-α levels decreased. Early and late activated T-cells were also reduced by MSC therapy.

Excellent Safety Profile: Of >100 patients treated no treatment associated adverse event is reported, the worst side-effect being temporary irritation at the injection site

Clinical trials

Tompkins, B.A. et al. (2017) ‘Allogeneic mesenchymal stem cells ameliorate aging frailty: A phase ii randomized, double-blind, placebo-controlled clinical trial’, The Journals of Gerontology: Series A, 72(11), pp. 1513–1522. doi:10.1093/gerona/glx137.

Golpanian, S. et al. (2017) ‘Allogeneic human mesenchymal stem cell infusions for aging frailty’, The Journals of Gerontology: Series A, 72(11), pp. 1505–1512. doi:10.1093/gerona/glx056.

Wang, X. et al. (2017) ‘Efficacy of protein extracts from medium of adipose-derived stem cells via microneedles on Asian skin’, Journal of Cosmetic and Laser Therapy, 20(4), pp. 237–244. doi:10.1080/14764172.2017.1400171.

Lee, Y.I. et al. (2020) ‘Randomized controlled study for the anti‐aging effect of human adipocyte‐derived mesenchymal stem cell media combined with niacinamide after laser therapy’, Journal of Cosmetic Dermatology, 20(6), pp. 1774–1781. doi:10.1111/jocd.13767.